BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 22, 2010
View Archived Issues
Archemix Could Get $315M in Baxter Hemophilia Assets Deal
Read More
Inspiration Starts Hemophilia Phase II/III, Collects $50M
Read More
Somaxon Adding $26M; Sales Efforts for Silenor Under Way
Read More
Stock Movers
Read More
White House Honors Top U.S. Scientists, Innovators
Read More
Clinic Roundup
Read More
Other News To Note
Read More
EORTC Roundup
Read More
Bench Press
Read More
Amgen Wins D-Mab OK for Fractures in Cancer Patients
WASHINGTON – The FDA late Thursday approved Amgen Inc.'s denosumab 120 mg as a therapy to prevent skeletal-related events (SRE) in patients with bone metastases from solid tumors. (BioWorld Today)
Read More
BTG Grabs Biocompatibles for $284.5M in All-Share Deal
Read More
